Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 medication and introduced a GLP-1 Supply Tracker, where individuals…
QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed…
Business Leaders and Industry Experts Join Top Policymakers to Address Pivotal Issues in Health Globally at the Milken Institute 2024 Future of Health Summit The Milken Institute 2024 Future of Health Summit opens today, gathering hundreds of renowned business leaders, health experts,…
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV…
VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership with Neurochase, the CNS (central nervous system) delivery platform specialist, to manufacture electrospun micro-catheters to deliver advanced therapies to the brain.UK-based Neurochase is a medical technology company developing a…
AstraZeneca and Amgen announced promising top-line results from the Phase III WAYPOINT trial, showing that Tezspire (tezepelumab) significantly reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo. The WAYPOINT trial, a…
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is gearing up for the sixth annual BOTOX® Cosmetic Day, set for Wednesday, November 20, 2024. This special day celebrates the healthcare providers and patients who have helped make BOTOX® Cosmetic the world’s…
Second Round of Polio Vaccination Campaign in Gaza Completed Amid Ongoing Conflict: UNICEF and WHO The second round of the polio vaccination campaign in the Gaza Strip concluded yesterday, with 556,774 children under the age of 10 receiving a second…
The Access and Allocation Mechanism (AAM) for mpox has allocated an initial 899,000 vaccine doses to nine African countries severely impacted by the ongoing mpox outbreak. This distribution, made in collaboration with affected nations and donors, aims to ensure effective…
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, will showcase new findings from the Phase 3 CARTITUDE-4 trial on minimal residual disease (MRD) negativity rates in multiple myeloma patients treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus standard…
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-driven cancers, reported its third-quarter financial results for the period ending September 30, 2024, and shared updates on corporate progress. The company’s mission centers on…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased findings from the long-term KINECT®-4 study, revealing that nearly 60% of participants achieved remission from tardive dyskinesia after 48 weeks of treatment with once-daily INGREZZA® (valbenazine) capsules. This research, titled “Remission of Tardive Dyskinesia…